Physician profile
Brian T Fowler
NPI 1093987893
$206,094.04
in general payments reported to CMS, 2019-2025
16 companies · $53K in 2025
The $53K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $130 · 2021: $148 · 2022: $2,598 · 2023: $72K · 2024: $77K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100K · Honoraria: $59K · Consulting Fee: $25K · Travel and Lodging: $16K · Food and Beverage: $2,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $99,950.00 |
| Honoraria | $58,525.00 |
| Consulting Fee | $25,200.00 |
| Travel and Lodging | $16,334.59 |
| Food and Beverage | $2,966.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $130,246.28 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $74,572.67 | 2019-2023 | Tepezza |
| Alcon Vision LLC | $436.32 | 2019-2024 | Clareon, Rocklatan |
| Stryker Corporation | $162.31 | 2023 | Core |
| Bausch & Lomb Americas INC. | $122.19 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $110.70 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $79.38 | 2019-2022 | |
| Biotissue Holdings INC. | $73.78 | 2021-2025 | |
| Ocular Therapeutix, INC. | $71.11 | 2025 | Dextenza |
| Allergan, INC. | $68.01 | 2020-2021 | |
| Ucb, INC. | $63.54 | 2023-2025 | Rystiggo |
| Vyera Pharmaceuticals, LLC | $22.80 | 2020 | |
| Shire North American Group INC | $21.42 | 2019 | |
| Genentech USA, INC. | $19.40 | 2019 | |
| Kala Pharmaceuticals, INC. | $12.62 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Fowler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.